Clifford Banda, a Clinical Research Associate and member of the Malaria Epidemiology Group at MLW, has been awarded a Clinical Research and Development Fellowship by the Special Programme for Research and Training in Tropical Diseases of the World Health Organisation (TDR). The aim of the training programme is to support the development of Fellows who can strengthen the conduct of clinical research related to poverty related diseases (i.e. malaria, HIV and TB) in developing countries, as well as increasing institutional collaboration between the fellow’s home and host organisations.
During his 18 month fellowship, Clifford will spend 9 months at the WorldWide Antimalarial Resistance Network (WWARN) at Oxford University -where he will be exposed to robust methods of analysing pooled individual patient data from clinical trials followed by a 3 months placement at WWARN’s Cape Town Centre at the University of Cape Town where he will work with Prof Karen Barnes (Head of Clinical Pharmacology within WWARN) to strengthen his clinical pharmacology skills. The latter will include Pharmacometrics and clinical trials work at the Collaborating Centre for Optimising Antimalarial Therapy whose work include early phase clinical trials. After returning from the WWARN placement, the fellowship will support a further 6-month re-integration period at MLW within the malaria epidemiology group under the supervision of Dr Eva Maria Hodel and Dr Anja Terlouw allowing him to apply the skills he would have acquired during his time at WWARN, and transition to his next career step.
Clifford, who recently completed his Masters in Epidemiology at the London School of Hygiene and Tropical Medicine, had this to say: “The fellowship is a unique training opportunity for me, it will allow me to apply the skills I have acquired during my masters training and it will help me in strengthening my research skills in clinical pharmacology. I believe WWARN will offer a stimulating training environment. The Fellowship will be vital for my career development, and fits well with the strategic development of pharmaco-epidemiology work at MLW”.